Literature DB >> 15923166

Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

Weg M Ongkeko1, Xabier Altuna, Robert A Weisman, Jessica Wang-Rodriguez.   

Abstract

Protein tyrosine kinases (TKs) are overexpressed in many carcinomas and sarcomas. We studied the expression of the following TKs in head and neck squamous cell carcinoma (HNSCC): platelet-derived growth factor receptor (PDGFR), c-kit, epidermal growth factor receptor (EGFR), and a serine-threonine kinase, Akt. Formalin-fixed, paraffin-embedded tumor blocks from 44 consecutive patients with primary HNSCC and 5 specimens of benign pharyngeal and laryngeal mucosa were retrieved for immunohistochemical analysis. Of the specimens, 38 had enough material to stain for all 4 antibodies. The study included 21 pharyngeal (base of tongue, 14; tonsil, 6; soft palate, 1), 16 laryngeal, and 1 floor of the mouth carcinoma. All 4 kinases in the tumor samples were expressed highly (PDGFR, 95%-100%; EGFR, 38%-43%; c-kit, 50%-86%; p-Akt, 57%-81%), with EGFR, c-kit, and p-Akt significantly higher than in benign samples. None of the kinase expressions correlated with disease-free survival. The expression of the kinases raises the possibility of treatment of HNSCC by tyrosine and serine-threonine kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923166     DOI: 10.1309/BTLN5WTMJ3PCNRRC

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

1.  A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.

Authors:  Takahiro Wakasaki; Muneyuki Masuda; Hiroaki Niiro; Siamak Jabbarzadeh-Tabrizi; Kumiko Noda; Tadayoshi Taniyama; Shizuo Komune; Koichi Akashi
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

3.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

4.  Molecular characterization of head and neck cancer: how close to personalized targeted therapy?

Authors:  Maria J Worsham; Haythem Ali; Jadranka Dragovic; Vanessa P Schweitzer
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 6.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

7.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

8.  Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Authors:  Ning Jiang; Dongsheng Wang; Zhongliang Hu; Hyung Ju C Shin; Guoqing Qian; Mohammad Aminur Rahman; Hongzheng Zhang; A R M Ruhul Amin; Sreenivas Nannapaneni; Xiaojing Wang; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Jun Ma; Zhuo G Chen; Nabil F Saba
Journal:  Mol Cancer Ther       Date:  2014-04-18       Impact factor: 6.261

9.  Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.

Authors:  L Dova; G Pentheroudakis; V Golfinopoulos; V Malamou-Mitsi; I Georgiou; G Vartholomatos; A Ntemou; G Fountzilas; N Pavlidis
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-07       Impact factor: 4.553

10.  Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Authors:  Nicholas W Choong; Mark Kozloff; David Taber; H Shawn Hu; James Wade; Percy Ivy; Theodore G Karrison; Allison Dekker; Everett E Vokes; Ezra E W Cohen
Journal:  Invest New Drugs       Date:  2009-08-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.